Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Phase 3ASP2138Positive

AI Analysis

Summary

Astellas Pharma has dosed the first patient in a Phase 3 trial of ASP2138 for CLDN18.2-positive and HER2-negative gastric or gastroesophageal junction adenocarcinoma, marking an important milestone in the company's CLDN18.2 research program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in Phase 3 study

Importance:6/10

Sentiment:

0.60

Phase 3Gastric cancerCLDN18.2Clinical trial milestone

Related Companies

$ALPMY

Read the original article

Published by PR Newswire Pharma on August 24, 2026 11:30 PM

Read Original